ClinicalTrials.gg
CompletedNCT03009487Updated Jan 11, 2022

A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia

A Phase 3 interventional study of Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg and Olmesartan 40 mg, Rosuvastatin 20mg in Hypertension and Hyperlipidemias, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 3 under way, none of them phase 3. Hypertension · Daewoong Pharmaceutical Co. LTD..

Enrollment
Largest of 10
265 · median 128
Started
2017
the only one that year
Phase 3
5 of 15
none open now
Registered
6th of 15
by date

Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 3, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Olmesartan/Amlodipine/Rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia

03

Conditions studied

  • Hypertension
  • Hyperlipidemias
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20 to 80 years
  • patients with hypertension and hyperlipidemias

Exclusion criteria

Exclusion Criteria:

  • orthostatic hypotension
  • History of ventricular tachycardia, atrial fibrillation
  • uncontrolled diabetes mellitus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Amlodpine, Olmesartan, Rosuvastatin

    co-administration of Olmesartan, Amlodipine and Rosuvastatin

    Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg

  • Placebo comparator
    Olmesartan, Rosuvastatin

    co-administration of Olmesartan and Rosuvastatin

    Drug: Olmesartan 40 mg, Rosuvastatin 20mg

  • Placebo comparator
    Amlodipine, Olmesartan

    co-administration of Amlodipine and and Olmesartan

    Drug: Amlodipine/Olmesartan 10/40mg (Combination drug)

Interventions

  • DrugAmlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg

    co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg

  • DrugOlmesartan 40 mg, Rosuvastatin 20mg

    co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).

  • DrugAmlodipine/Olmesartan 10/40mg (Combination drug)

    co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg

06

What researchers measure

Primary outcomes

  1. the change of sitSBP based on baseline between Treatment arm and control 1 arm

    Time frame: 8 weeks

  2. the change of LDL-C based on baseline between Treatment arm and control2 arm

    Time frame: 8 weeks

07

Study locations

1 site
  • Seoul national university bundang hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2018, 15 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 15 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2016
First posted
Jan 4, 2017
StartActual
Jan 2017
Primary completionActual
Apr 2018
CompletionActual
Apr 2018
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03009487
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Jan 2017
Primary completion
Apr 2018
Completion
Apr 2018
Last update
Jan 11, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion